Shandong Lukang Pharmaceutical announced that the company recently received the 'Drug Clinical Trial Approval Notice' for Injectable CIGB-814 issued by the National Medical Products Administration. This pharmaceutical is a type 1 innovative drug, clinically intended for adults with active rheumatoid arthritis. As of now, the company has accumulated approximately 82.0565 million RMB in research and development investment for this project. The sales of related drugs for rheumatoid arthritis in the domestic market are estimated to be around 4.8 billion yuan in 2023.
- Latest
- Detail
鲁抗医药：注射用CIGB-814获临床试验批准
Shandong Lukang Pharmaceutical: Injectable CIGB-814 has obtained clinical trial approval.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
11:33
Shanghai's seven departments have issued a notice to further strengthen the pilot work of skills training in the integrated circuit, biomedical, ai three major leading industries, as well as retirement care and domestic service industries.
CNI Biomedicine Index-0.66%
11:29
Kaituomacro: South Korea's overall economy still faces risks.
11:26
Guangzhou: Operation subsidies are provided to hydrogen stations accessing the national, provincial, and municipal fuel cell autos demonstration application related information platforms.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.